Skip to Main Content

Paper Details

Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Future Oncol
19
2021
Author NameAffiliation
Robert S EpsteinEpstein Health LLC
  • 1 - 1

Datasets

Release 1.2